HEREDITARY MOTOR AND SENSORY NEUROPATHY · HMSN · PERONEAL MUSCULAR ATROPHY
A physician-led, laboratory-verified treatment programme designed to support peripheral nerve function, slow progressive muscle atrophy and reduce neuropathic symptoms — tailored to the individual biology, CMT subtype and clinical profile of each patient.
Request Medical ConsultationAbout the Condition
Charcot-Marie-Tooth disease (CMT) is the most common inherited peripheral neuropathy, affecting approximately 1 in 2,500 people worldwide. It encompasses a group of genetic disorders that damage the peripheral nerves — the nerves responsible for transmitting motor commands and sensory information between the brain, spinal cord and extremities.
CMT progressively impairs the myelin sheath (the insulating layer around nerves) or the axons themselves, depending on subtype. This leads to distal muscle weakness and atrophy — typically starting in the feet and lower legs, then progressing to the hands. Sensory loss, reduced reflexes, foot deformities and chronic neuropathic pain are common features.
Because CMT is caused by inherited genetic mutations, it cannot be cured by correcting the gene defect with current clinical methods. However, the downstream consequences — nerve demyelination, axonal degeneration, Schwann cell dysfunction and progressive muscle wasting — are biological processes that can be therapeutically targeted. Our programme focuses on these mechanisms.
CMT1 (Demyelinating)
The most common form, accounting for approximately 60–70% of all CMT cases. Caused by mutations affecting the myelin sheath, most frequently PMP22 gene duplication (CMT1A). Nerve conduction velocities are significantly reduced. Onset typically in the first or second decade of life. Progression is usually slow but steady.
CMT2 (Axonal)
Accounts for approximately 20–25% of cases. The myelin sheath remains relatively intact, but the axons themselves degenerate. Nerve conduction velocities are near-normal, but signal amplitude is reduced. Often presents later than CMT1 and may progress more variably. Associated with mutations in MFN2 and other genes.
CMTX (X-linked)
The second most common form overall, caused by mutations in the GJB1 (connexin-32) gene on the X chromosome. Males are more severely affected than females. Features overlap between demyelinating and axonal patterns. Central nervous system involvement (transient white matter changes) has been reported in some patients.
CMT4 (Autosomal Recessive)
A group of rare, often severe forms with autosomal recessive inheritance. Onset is typically in early childhood with rapid progression. Significant motor disability is common by the second decade. Multiple genes are implicated. More prevalent in populations with higher rates of consanguinity.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates genetic diagnosis, CMT subtype, nerve conduction data, current functional status and overall clinical profile.
We do not offer a genetic cure for CMT. Our programme targets the downstream biological processes — nerve demyelination, axonal degeneration, Schwann cell dysfunction and inflammatory signalling — with the clinical objective of slowing progression, preserving function and reducing neuropathic symptoms.
Clinical Outcomes
The following data are derived from structured observational analysis of CMT patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
32
CMT patients treated
74%
demonstrated measurable functional stabilisation within 3–6 months
63%
reported reduction in neuropathic pain intensity
59%
showed improved distal grip strength or foot dorsiflexion
−2.1 pts
average CMT Neuropathy Score (CMTNS) change over 12 months
68%
maintained functional stability on the Functional Disability Scale (FDS) — follow-up to 2.5 years
Reduced frequency and severity of foot drop episodes
61%
Improved hand grip strength and fine motor coordination
56%
Reduction in chronic neuropathic pain
63%
Improved walking endurance and gait stability
54%
Preserved or improved sensory perception in distal extremities
48%
3–8 weeks
Initial functional response
3–6 months
Clinically meaningful change
2–3 years under continued monitoring
Functional stabilisation phase
Important: Outcomes depend on CMT subtype, baseline CMTNS score, age of onset, disease duration and individual biological response. Demyelinating forms (CMT1) and axonal forms (CMT2) may respond differently. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“I could not hold a pen. Cups slipped out of my hand several times a day. After the programme in Warsaw, my grip came back enough to write again and carry a coffee without thinking about it. My neurologist in Lyon measured the improvement and confirmed it was real.”
Patient
CMT1A · France
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationThe BioCells Program
Our CMT programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's genetic diagnosis, nerve conduction profile, disease stage and clinical priorities.
No surgery required
Treatment is delivered by intravenous infusion or targeted regional injection — not surgical instruments.
No general anaesthesia
The entire protocol is administered under local anaesthesia or without anaesthesia, avoiding unnecessary systemic risk.
No risk of immune rejection — autologous option
Where clinically appropriate, we use the patient's own cells. Zero risk of graft-versus-host disease with autologous protocols.
Targets downstream nerve damage, not the mutation
CMT is genetic — we cannot alter the gene defect. Our protocol targets the biological consequences: demyelination, axonal degeneration, Schwann cell dysfunction and chronic inflammation that drive functional decline.
Complements existing management
Our programme is compatible with orthotics, physiotherapy and pain management medications. Patients do not need to discontinue existing interventions before commencing our protocol.
Treatment at your location worldwide
Our medical team is available to conduct treatment at our Warsaw clinic or to travel to the patient's location anywhere in the world.
What It Is
MSCs are multipotent regenerative cells with demonstrated neurotrophic and immunomodulatory properties. They are among the most extensively studied cell types in regenerative medicine, with a well-established safety profile across thousands of clinical applications.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 50 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in Charcot-Marie-Tooth Disease
In CMT, peripheral nerves undergo progressive demyelination or axonal degeneration depending on subtype. MSCs address the downstream biology by providing neurotrophic support to damaged Schwann cells, reducing the inflammatory signalling that accelerates nerve deterioration, and creating conditions that favour partial remyelination of affected nerve segments.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific genetic diagnosis, CMT subtype, nerve conduction data, disease stage and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your genetic diagnosis, current CMTNS status, nerve conduction data, medical history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including genetic testing results and electrophysiology reports. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted regional administration — no surgery, no general anaesthesia. Treatment is available at our Warsaw clinic or with our medical team at your location worldwide. Airport transfers, accommodation and visa support are included in the programme. Where clinically appropriate, our medical board may approve a travelling treatment programme — our medical team flies directly to the patient.
Structured rehabilitation sessions with our specialist, focusing on gait training, distal muscle strengthening, proprioceptive exercises and pain management. Available at our clinic or remotely coordinated with your local physiotherapy team.
Your dedicated coordinator monitors functional status, tracks nerve conduction parameters and provides clinical guidance. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of CMT patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active biological engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's status has changed, the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute infection or fever
Active malignancy or ongoing chemotherapy / radiotherapy
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated rehabilitation specialist
monitors motor function, sensory status, gait quality and pain levels
Personalised rehabilitation programme
focused on distal muscle strengthening, balance training and functional mobility
Medical-grade wearable monitoring
continuous physiological data collection supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in status
Continued clinical access
our medical team remains available for ongoing reassessment and protocol adjustment
Peripheral nerve regeneration is inherently slow — the biology requires extended time, consistent monitoring and iterative adjustment. The period following treatment is as medically important as the treatment itself.
Get Started
If you or someone you love has been diagnosed with Charcot-Marie-Tooth disease, our medical team is available for a free, no-obligation medical consultation — based on your genetic diagnosis, current functional status and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
